The American Thyroid Association is holding its annual meeting as a virtual event on September 30th- October 3rd.
This item is interesting, It shows that in the US and certain members in the UK that a basic change is being talked about regarding the value of FT3 in diagnosis and T3 or related T3-substitutes as a prescription for thyroid disease. Looks as if the present beliefs are changing. Our group won't be mentioned I'm certain.
Treatments for Hypothyroidism-A Changing Paradigm
Jacqueline Jonklaas, MD, PhD, “How to Use LT3 + LT4 today”
Colin Dayan, MA, FRCP, PhD, “Clinical trials under way”
Antonio Bianco, MD, PhD, “New Formulations of Liothyronine”